Study to Treat Major Depressive Disorder With a New Medication

Phase 2 Completed 45 enrolled James Murrough Baylor College of Medicine · collab National Institute of Mental Health (NIMH) · collab

RandomizedParallel-groupDouble-blindOther

Summary

This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener ezogabine (Potiga, GlaxoSmithKline; FDA-approved for the treatment of seizure disorders).

Timeline

Start: 2017-09-25
Primary completion: 2019-08-30
Completion: 2019-08-30

Outcome

Missed primary endpoint

paper The study did not meet its primary neuroimaging endpoint. PMID 33653118 ↗

Publications

Costi S, Morris LS, Kirkwood KA, Hoch M, Corniquel M, Vo-Le B, Iqbal T, Chadha N, Pizzagalli DA, Whitton A, Bevilacqua L, Jha MK, Ursu S, Swann AC, Collins KA, Salas R, Bagiella E, Parides MK, Stern ER, Iosifescu DV, Han MH, Mathew SJ, Murrough JW. Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. Am J Psychiatry. 2021 May 1;178(5):437-446. doi: 10.1176/appi.ajp.2020.20050653. Epub 2021 Mar 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ezogabine	Small molecule	900 mg	—